Disease Outcomes With Ublituximab in Treatment-Naive Participants: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 10/26/2022
B-Cell Depletion and Return in Participant Subgroups of the Phase 3 ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis By admin / 10/26/2022
Improved Quality of Life With Ublituximab in the ULTIMATE I and II Studies in Relapsing Multiple Sclerosis By admin / 06/27/2022
Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis: Pooled Post Hoc Analyses of the ULTIMATE I and II Studies By admin / 06/27/2022
Ublituximab Efficacy Outcomes in Relapsing Multiple Sclerosis Patient Subgroups in the ULTIMATE I and II Studies By admin / 06/26/2022
Improved Cognitive Processing Speed With Ublituximab in Patients With Highly Active Relapsing Multiple Sclerosis By admin / 06/02/2022
Infusion-Related Reactions With Ublituximab in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis By admin / 06/02/2022
Reduced Disease Progression With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis By admin / 06/02/2022
Relapse Rate and Time to First Relapse were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS) By admin / 04/05/2022
